Exelixis stock trades at EUR 63.66 on Lang & Schwarz Friday

Published on 10/30/2026 at 19:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Exelixis stock was quoted on Lang & Schwarz in Friday evening trading. The biotechnology company develops and markets cancer treatments.

Company and trading context

Exelixis develops and markets oncology treatments, including CABOMETYX and COMETRIQ.
The biotechnology company is advancing pipeline candidates such as XL092, XB002 and XL102.

EXEL, US30161Q1040, Illustration mit AI erstellt.

Exelixis stock traded at 63.66 euros on Lang & Schwarz at 7:08 p.m. CET on Friday, October 30, 2026.

Oncology portfolio remains central

Exelixis is a biotechnology company focused on identifying, developing and commercializing oncology treatments in the United States. Its commercial portfolio includes CABOMETYX and COMETRIQ, both based on the active ingredient cabozantinib, as well as COTELLIC.

The company is also advancing candidates including XL092, an oral tyrosine kinase inhibitor, XB002, an antibody-drug conjugate, and XL102, a CDK7 inhibitor for advanced or metastatic solid tumors.

Investors can follow the real-time quote of Exelixis stock for the latest Lang & Schwarz indication.

In the broader U.S. market, investors also track the S&P 500.

More news and analyses on Exelixis stock